{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T22:49:28Z","timestamp":1744066168419,"version":"3.40.3"},"publisher-location":"New York, NY","reference-count":146,"publisher":"Springer US","isbn-type":[{"type":"print","value":"9781071609118"},{"type":"electronic","value":"9781071609125"}],"license":[{"start":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T00:00:00Z","timestamp":1597708800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T00:00:00Z","timestamp":1597708800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1007\/978-1-0716-0912-5_5","type":"book-chapter","created":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T21:06:05Z","timestamp":1597698365000},"page":"109-135","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Trials for Motor Complications in Parkinson\u2019s Disease"],"prefix":"10.1007","author":[{"given":"Tiago A.","family":"Mestre","sequence":"first","affiliation":[]},{"given":"Joaquim J.","family":"Ferreira","sequence":"additional","affiliation":[]},{"given":"Olivier","family":"Rascol","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2020,8,18]]},"reference":[{"issue":"12","key":"5_CR1","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G (2015) MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord 30(12):1591\u20131601. https:\/\/doi.org\/10.1002\/mds.26424","journal-title":"Mov Disord"},{"key":"5_CR2","doi-asserted-by":"publisher","unstructured":"Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, Hametner EM, Poewe W, Rascol O, Goetz CG, Sampaio C (2011) The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson\u2019s disease. Mov Disord 26 Suppl 3:S42\u2013S80. https:\/\/doi.org\/10.1002\/mds.23884","DOI":"10.1002\/mds.23884"},{"issue":"5","key":"5_CR3","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/ana.410390504","volume":"39","author":"JG Nutt","year":"1996","unstructured":"Nutt JG, Holford NH (1996) The response to levodopa in Parkinson\u2019s disease: imposing pharmacological law and order. Ann Neurol 39(5):561\u2013573. https:\/\/doi.org\/10.1002\/ana.410390504","journal-title":"Ann Neurol"},{"issue":"1","key":"5_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/mds.21060","volume":"22","author":"JG Nutt","year":"2007","unstructured":"Nutt JG (2007) Continuous Dopaminergic stimulation: is it the answer to the motor complications of levodopa. Mov Disord 22(1):1\u20139. https:\/\/doi.org\/10.1002\/mds.21060","journal-title":"Mov Disord"},{"issue":"2","key":"5_CR5","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/mds.20324","volume":"20","author":"MA Hely","year":"2005","unstructured":"Hely MA, Morris JGL, Reid WGJ, Trafficante R (2005) Sydney multicenter study of Parkinson\u2019s disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 20(2):190\u2013199","journal-title":"Mov Disord"},{"issue":"3","key":"5_CR6","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","volume":"16","author":"JE Ahlskog","year":"2001","unstructured":"Ahlskog JE, Muenter MD (2001) Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16(3):448\u2013458","journal-title":"Mov Disord"},{"issue":"12","key":"5_CR7","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1111\/ene.13466","volume":"24","author":"S Perez-Lloret","year":"2017","unstructured":"Perez-Lloret S, Negre-Pages L, Damier P, Delval A, Derkinderen P, Destee A, Meissner WG, Tison F, Rascol O (2017) L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: the COPARK survey. Eur J Neurol 24(12):1532\u20131538. https:\/\/doi.org\/10.1111\/ene.13466","journal-title":"Eur J Neurol"},{"issue":"12","key":"5_CR8","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1001\/archneur.63.12.1756","volume":"63","author":"RA Hauser","year":"2006","unstructured":"Hauser RA, McDermott MP, Messing S (2006) Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol 63(12):1756\u20131760. https:\/\/doi.org\/10.1001\/archneur.63.12.1756","journal-title":"Arch Neurol"},{"issue":"24","key":"5_CR9","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1056\/NEJMoa033447","volume":"351","author":"S Fahn","year":"2004","unstructured":"Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K, Group PS (2004) Levodopa and the progression of Parkinson\u2019s disease. N Engl J Med 351(24):2498\u20132508. https:\/\/doi.org\/10.1056\/NEJMoa033447","journal-title":"N Engl J Med"},{"issue":"4","key":"5_CR10","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1056\/NEJMoa1809983","volume":"380","author":"V CVM","year":"2019","unstructured":"CVM V, Suwijn SR, Boel JA, Post B, Bloem BR, van Hilten JJ, van Laar T, Tissingh G, Munts AG, Deuschl G, Lang AE, MGW D, de Haan RJ, de Bie RMA, Group LS (2019) Randomized delayed-start trial of levodopa in Parkinson\u2019s disease. N Engl J Med 380(4):315\u2013324. https:\/\/doi.org\/10.1056\/NEJMoa1809983","journal-title":"N Engl J Med"},{"issue":"1","key":"5_CR11","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/ana.22060","volume":"68","author":"F Stocchi","year":"2010","unstructured":"Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow CW (2010) Initiating levodopa\/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 68(1):18\u201327. https:\/\/doi.org\/10.1002\/ana.22060","journal-title":"Ann Neurol"},{"issue":"8","key":"5_CR12","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/mds.25364","volume":"28","author":"C Warren Olanow","year":"2013","unstructured":"Warren Olanow C, Kieburtz K, Rascol O, Poewe W, Schapira AH, Emre M, Nissinen H, Leinonen M, Stocchi F (2013) Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson\u2019s disease. Mov Disord 28(8):1064\u20131071. https:\/\/doi.org\/10.1002\/mds.25364","journal-title":"Mov Disord"},{"issue":"Pt 10","key":"5_CR13","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1093\/brain\/awu195","volume":"137","author":"R Cilia","year":"2014","unstructured":"Cilia R, Akpalu A, Sarfo FS, Cham M, Amboni M, Cereda E, Fabbri M, Adjei P, Akassi J, Bonetti A, Pezzoli G (2014) The modern pre-levodopa era of Parkinson\u2019s disease: insights into motor complications from sub-Saharan Africa. Brain 137(Pt 10):2731\u20132742. https:\/\/doi.org\/10.1093\/brain\/awu195","journal-title":"Brain"},{"issue":"1","key":"5_CR14","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/mds.26125","volume":"30","author":"CC Aquino","year":"2015","unstructured":"Aquino CC, Fox SH (2015) Clinical spectrum of levodopa-induced complications. Mov Disord 30(1):80\u201389. https:\/\/doi.org\/10.1002\/mds.26125","journal-title":"Mov Disord"},{"issue":"9","key":"5_CR15","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/s1474-4422(18)30239-4","volume":"17","author":"R Katzenschlager","year":"2018","unstructured":"Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, Henriksen T, van Laar T, Spivey K, Vel S, Staines H, Lees A (2018) Apomorphine subcutaneous infusion in patients with Parkinson\u2019s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol 17(9):749\u2013759. https:\/\/doi.org\/10.1016\/s1474-4422(18)30239-4","journal-title":"Lancet Neurol"},{"issue":"2","key":"5_CR16","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1474-4422(13)70293-X","volume":"13","author":"CW Olanow","year":"2014","unstructured":"Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, Vanagunas A, Othman AA, Widnell KL, Robieson WZ, Pritchett Y, Chatamra K, Benesh J, Lenz RA, Antonini A, Group LHS (2014) Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson\u2019s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 13(2):141\u2013149. https:\/\/doi.org\/10.1016\/S1474-4422(13)70293-X","journal-title":"Lancet Neurol"},{"key":"5_CR17","doi-asserted-by":"publisher","unstructured":"Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RMA, Seppi K, Coelho M, Sampaio C (2018) International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson\u2019s disease. Mov Disord. https:\/\/doi.org\/10.1002\/mds.27372","DOI":"10.1002\/mds.27372"},{"key":"5_CR18","first-page":"153","volume-title":"Recent developments in Parkinson\u2019s disease","author":"S Fahn","year":"1987","unstructured":"Fahn S, Elton R, Committee. MotUD (1987) The unified Parkinson\u2019s disease rating scale. In: Fahn SMC, Calne DB, Goldstein M (eds) Recent developments in Parkinson\u2019s disease, vol 2. Macmillan Health Care Information, Florham Park, NJ, pp 153\u2013163"},{"issue":"15","key":"5_CR19","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, LaPelle N, Force MDSURT (2008) Movement disorder society-sponsored revision of the unified Parkinson\u2019s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23(15):2129\u20132170. https:\/\/doi.org\/10.1002\/mds.22340","journal-title":"Mov Disord"},{"issue":"3","key":"5_CR20","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/jnnp.2003.022780","volume":"75","author":"J Reimer","year":"2004","unstructured":"Reimer J, Grabowski M, Lindvall O, Hagell P (2004) Use and interpretation of on\/off diaries in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 75(3):396\u2013400","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"5_CR21","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/j.1755-5949.2011.00253.x","volume":"18","author":"S Papapetropoulos","year":"2012","unstructured":"Papapetropoulos S (2012) Patient diaries as a clinical endpoint in Parkinson\u2019s disease clinical trials. CNS Neurosci Ther 18(5):380\u2013387. https:\/\/doi.org\/10.1111\/j.1755-5949.2011.00253.x","journal-title":"CNS Neurosci Ther"},{"issue":"5","key":"5_CR22","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/mds.23638","volume":"26","author":"RA Hauser","year":"2011","unstructured":"Hauser RA, Auinger P, Group PS (2011) Determination of minimal clinically important change in early and advanced Parkinson\u2019s disease. Mov Disord 26(5):813\u2013818. https:\/\/doi.org\/10.1002\/mds.23638","journal-title":"Mov Disord"},{"issue":"9","key":"5_CR23","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1002\/mds.23072","volume":"25","author":"C Colosimo","year":"2010","unstructured":"Colosimo C, Mart\u00ednez-Mart\u00edn P, Fabbrini G, Hauser RA, Merello M, Miyasaki J, Poewe W, Sampaio C, Rascol O, Stebbins GT, Schrag A, Goetz CG (2010) Task force report on scales to assess dyskinesia in Parkinson\u2019s disease: critique and recommendations. Mov Disord 25(9):1131\u20131142. https:\/\/doi.org\/10.1002\/mds.23072","journal-title":"Mov Disord"},{"issue":"3","key":"5_CR24","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/mds.25321","volume":"28","author":"CG Goetz","year":"2013","unstructured":"Goetz CG, Stebbins GT, Chung KA, Hauser RA, Miyasaki JM, Nicholas AP, Poewe W, Seppi K, Rascol O, Stacy MA, Nutt JG, Tanner CM, Urkowitz A, Jaglin JA, Ge S (2013) Which dyskinesia scale best detects treatment response? Mov Disord 28(3):341\u2013346. https:\/\/doi.org\/10.1002\/mds.25321","journal-title":"Mov Disord"},{"issue":"5","key":"5_CR25","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1002\/mds.21894","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Wuu J, McDermott MP, Adler CH, Fahn S, Freed CR, Hauser RA, Olanow WC, Shoulson I, Tandon PK, Leurgans S, Group PS (2008) Placebo response in Parkinson\u2019s disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord 23(5):690\u2013699. https:\/\/doi.org\/10.1002\/mds.21894","journal-title":"Mov Disord"},{"issue":"5","key":"5_CR26","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/mds.21897","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Laska E, Hicking C, Damier P, M\u00fcller T, Nutt J, Warren Olanow C, Rascol O, Russ H (2008) Placebo influences on dyskinesia in Parkinson\u2019s disease. Mov Disord 23(5):700\u2013707. https:\/\/doi.org\/10.1002\/mds.21897","journal-title":"Mov Disord"},{"issue":"3","key":"5_CR27","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/mds.26500","volume":"31","author":"TA Mestre","year":"2016","unstructured":"Mestre TA, Lang AE, Okun MS (2016) Factors influencing the outcome of deep brain stimulation: placebo, nocebo, lessebo, and lesion effects. Mov Disord 31(3):290\u2013296. https:\/\/doi.org\/10.1002\/mds.26500","journal-title":"Mov Disord"},{"issue":"6","key":"5_CR28","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/s1474-4422(11)70097-7","volume":"10","author":"RE Gross","year":"2011","unstructured":"Gross RE, Watts RL, Hauser RA, Bakay RA, Reichmann H, von Kummer R, Ondo WG, Reissig E, Eisner W, Steiner-Schulze H, Siedentop H, Fichte K, Hong W, Cornfeldt M, Beebe K, Sandbrink R (2011) Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson\u2019s disease: a double-blind, randomised, controlled trial. Lancet Neurol 10(6):509\u2013519. https:\/\/doi.org\/10.1016\/s1474-4422(11)70097-7","journal-title":"Lancet Neurol"},{"issue":"7","key":"5_CR29","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/ncpneuro0222","volume":"2","author":"W Olanow","year":"2006","unstructured":"Olanow W, Obeso JA, Stocchi F (2006) Drug insight: continuous dopaminergic stimulation in the treatment of Parkinson\u2019s disease. Nat Clin Pract Neurol 2(7):382\u2013392. https:\/\/doi.org\/10.1038\/ncpneuro0222","journal-title":"Nat Clin Pract Neurol"},{"issue":"10","key":"5_CR30","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1001\/archneur.1987.00520220016008","volume":"44","author":"JL Juncos","year":"1987","unstructured":"Juncos JL, Fabbrini G, Mouradian MM, Chase TN (1987) Controlled release levodopa-carbidopa (CR-5) in the management of parkinsonian motor fluctuations. Arch Neurol 44(10):1010\u20131012. https:\/\/doi.org\/10.1001\/archneur.1987.00520220016008","journal-title":"Arch Neurol"},{"issue":"1","key":"5_CR31","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1600-0404.1996.tb00163.x","volume":"93","author":"E Dupont","year":"1996","unstructured":"Dupont E, Andersen A, Boas J, Boisen E, Borgmann R, Helgetveit AC, Kjaer MO, Kristensen TN, Mikkelsen B, Pakkenberg H, Presthus J, Stien R, Worm-Petersen J, Buch D (1996) Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients. Acta Neurol Scand 93(1):14\u201320","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"5_CR32","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/S1474-4422(13)70025-5","volume":"12","author":"RA Hauser","year":"2013","unstructured":"Hauser RA, Hsu A, Kell S, Espay AJ, Sethi K, Stacy M, Ondo W, O\u2019Connell M, Gupta S, investigators IA-P (2013) Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson\u2019s disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol 12(4):346\u2013356. https:\/\/doi.org\/10.1016\/S1474-4422(13)70025-5","journal-title":"Lancet Neurol"},{"issue":"12","key":"5_CR33","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1002\/mds.23206","volume":"25","author":"F Stocchi","year":"2010","unstructured":"Stocchi F, Zappia M, Dall\u2019Armi V, Kulisevsky J, Lamberti P, Obeso JA (2010) Melevodopa\/carbidopa effervescent formulation in the treatment of motor fluctuations in advanced Parkinson\u2019s disease. Mov Disord 25(12):1881\u20131887. https:\/\/doi.org\/10.1002\/mds.23206","journal-title":"Mov Disord"},{"key":"5_CR34","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/369465","volume":"2015","author":"F Stocchi","year":"2015","unstructured":"Stocchi F, Vacca L, Grassini P, Pawsey S, Whale H, Marconi S, Torti M (2015) L-Dopa pharmacokinetic profile with effervescent melevodopa\/carbidopa versus standard-release levodopa\/carbidopa tablets in Parkinson\u2019s disease: a randomised study. Parkinson\u2019s Dis 2015:369465. https:\/\/doi.org\/10.1155\/2015\/369465","journal-title":"Parkinson\u2019s Dis"},{"issue":"2","key":"5_CR35","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/mds.10075","volume":"17","author":"R Djaldetti","year":"2002","unstructured":"Djaldetti R, Inzelberg R, Giladi N, Korczyn AD, Peretz-Aharon Y, Rabey MJ, Herishano Y, Honigman S, Badarny S, Melamed E (2002) Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson\u2019s disease. Mov Disord 17(2):297\u2013302","journal-title":"Mov Disord"},{"issue":"9","key":"5_CR36","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1002\/mds.26219","volume":"30","author":"L Verhagen Metman","year":"2015","unstructured":"Verhagen Metman L, Stover N, Chen C, Cowles VE, Sweeney M (2015) Gastroretentive carbidopa\/levodopa, DM-1992, for the treatment of advanced Parkinson\u2019s disease. Mov Disord 30(9):1222\u20131228. https:\/\/doi.org\/10.1002\/mds.26219","journal-title":"Mov Disord"},{"issue":"5","key":"5_CR37","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/j.1468-1331.1997.tb00388.x","volume":"4","author":"A Monge","year":"1997","unstructured":"Monge A, Barbato L, Nordera G, Stocchi F (1997) An acute and long-term study with a dispersible formulation of levodopa\/benserazide (Madopar(R)) in Parkinson\u2019s disease. Eur J Neurol 4(5):485\u2013490. https:\/\/doi.org\/10.1111\/j.1468-1331.1997.tb00388.x","journal-title":"Eur J Neurol"},{"key":"5_CR38","doi-asserted-by":"publisher","unstructured":"LeWitt PA, Giladi N, Navon N (2019) Pharmacokinetics and efficacy of a novel formulation of carbidopa-levodopa (Accordion Pill). Parkinsonism Relat Disord. https:\/\/doi.org\/10.1016\/j.parkreldis.2019.05.032","DOI":"10.1016\/j.parkreldis.2019.05.032"},{"issue":"3","key":"5_CR39","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/WNF.0b013e31824e4d7d","volume":"35","author":"PA Lewitt","year":"2012","unstructured":"Lewitt PA, Ellenbogen A, Chen D, Lal R, McGuire K, Zomorodi K, Luo W, Huff FJ (2012) Actively transported levodopa prodrug XP21279: a study in patients with Parkinson disease who experience motor fluctuations. Clin Neuropharmacol 35(3):103\u2013110. https:\/\/doi.org\/10.1097\/WNF.0b013e31824e4d7d","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"5_CR40","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/mds.25742","volume":"29","author":"PA LeWitt","year":"2014","unstructured":"LeWitt PA, Huff FJ, Hauser RA, Chen D, Lissin D, Zomorodi K, Cundy KC (2014) Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson\u2019s disease. Mov Disord 29(1):75\u201382. https:\/\/doi.org\/10.1002\/mds.25742","journal-title":"Mov Disord"},{"key":"5_CR41","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ensci.2018.09.003","volume":"13","author":"M Nomoto","year":"2018","unstructured":"Nomoto M, Nagai M, Nishikawa N, Ando R, Kagamiishi Y, Yano K, Saito S, Takeda A (2018) Pharmacokinetics and safety\/efficacy of levodopa pro-drug ONO-2160\/carbidopa for Parkinson\u2019s disease. eNeurologicalSci 13:8\u201313. https:\/\/doi.org\/10.1016\/j.ensci.2018.09.003","journal-title":"eNeurologicalSci"},{"issue":"2","key":"5_CR42","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/mds.21225","volume":"22","author":"S Junghanns","year":"2007","unstructured":"Junghanns S, Fuhrmann JT, Simonis G, Oelwein C, Koch R, Strasser RH, Reichmann H, Storch A (2007) Valvular heart disease in Parkinson\u2019s disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study. Mov Disord 22(2):234\u2013238. https:\/\/doi.org\/10.1002\/mds.21225","journal-title":"Mov Disord"},{"key":"5_CR43","doi-asserted-by":"publisher","unstructured":"Clarke CE, Speller JM, Clarke JA (2000) Pramipexole for levodopa-induced complications in Parkinson\u2019s disease. Cochrane Database Syst Rev (3):Cd002261. https:\/\/doi.org\/10.1002\/14651858.cd002261","DOI":"10.1002\/14651858.cd002261"},{"key":"5_CR44","doi-asserted-by":"publisher","unstructured":"Clarke CE, Deane KH (2001) Ropinirole for levodopa-induced complications in Parkinson\u2019s disease. Cochrane Database Syst Rev (1):CD001516. https:\/\/doi.org\/10.1002\/14651858.CD001516","DOI":"10.1002\/14651858.CD001516"},{"issue":"8","key":"5_CR45","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1212\/WNL.0b013e31822affdb","volume":"77","author":"AH Schapira","year":"2011","unstructured":"Schapira AH, Barone P, Hauser RA, Mizuno Y, Rascol O, Busse M, Salin L, Juhel N, Poewe W (2011) Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial. Neurology 77(8):767\u2013774. https:\/\/doi.org\/10.1212\/WNL.0b013e31822affdb","journal-title":"Neurology"},{"issue":"6","key":"5_CR46","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/ene.13303","volume":"24","author":"T Shen","year":"2017","unstructured":"Shen T, Ye R, Zhang B (2017) Efficacy and safety of pramipexole extended-release in Parkinson\u2019s disease: a review based on meta-analysis of randomized controlled trials. Eur J Neurol 24(6):835\u2013843. https:\/\/doi.org\/10.1111\/ene.13303","journal-title":"Eur J Neurol"},{"issue":"14","key":"5_CR47","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1212\/01.wnl.0000258660.74391.c1","volume":"68","author":"R Pahwa","year":"2007","unstructured":"Pahwa R, Stacy MA, Factor SA, Lyons KE, Stocchi F, Hersh BP, Elmer LW, Truong DD, Earl NL, Investigators E-PAS (2007) Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 68(14):1108\u20131115. https:\/\/doi.org\/10.1212\/01.wnl.0000258660.74391.c1","journal-title":"Neurology"},{"issue":"7","key":"5_CR48","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1002\/mds.23498","volume":"26","author":"F Stocchi","year":"2011","unstructured":"Stocchi F, Giorgi L, Hunter B, Schapira AHV (2011) PREPARED: comparison of prolonged and immediate release ropinirole in advanced Parkinson\u2019s disease. Mov Disord 26(7):1259\u20131265. https:\/\/doi.org\/10.1002\/mds.23498","journal-title":"Mov Disord"},{"issue":"7","key":"5_CR49","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1002\/mds.23498","volume":"26","author":"F Stocchi","year":"2011","unstructured":"Stocchi F, Giorgi L, Hunter B, Schapira AH (2011) PREPARED: comparison of prolonged and immediate release ropinirole in advanced Parkinson\u2019s disease. Mov Disord 26(7):1259\u20131265. https:\/\/doi.org\/10.1002\/mds.23498","journal-title":"Mov Disord"},{"issue":"16","key":"5_CR50","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1212\/01.wnl.0000259516.61938.bb","volume":"68","author":"PA LeWitt","year":"2007","unstructured":"LeWitt PA, Lyons KE, Pahwa R, Group SS (2007) Advanced Parkinson disease treated with rotigotine transdermal system: PREFER study. Neurology 68(16):1262\u20131267. https:\/\/doi.org\/10.1212\/01.wnl.0000259516.61938.bb","journal-title":"Neurology"},{"issue":"1","key":"5_CR51","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.1468-1331.2011.03442.x","volume":"19","author":"KR Chaudhuri","year":"2012","unstructured":"Chaudhuri KR, Martinez-Martin P, Rolfe KA, Cooper J, Rockett CB, Giorgi L, Ondo WG (2012) Improvements in nocturnal symptoms with ropinirole prolonged release in patients with advanced Parkinson\u2019s disease. Eur J Neurol 19(1):105\u2013113. https:\/\/doi.org\/10.1111\/j.1468-1331.2011.03442.x","journal-title":"Eur J Neurol"},{"issue":"1","key":"5_CR52","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/mds.23441","volume":"26","author":"C Trenkwalder","year":"2011","unstructured":"Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, Dioszeghy P, Hill D, Anderson T, Myllyla V, Kassubek J, Steiger M, Zucconi M, Tolosa E, Poewe W, Surmann E, Whitesides J, Boroojerdi B, Chaudhuri KR (2011) Rotigotine effects on early morning motor function and sleep in Parkinson\u2019s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 26(1):90\u201399. https:\/\/doi.org\/10.1002\/mds.23441","journal-title":"Mov Disord"},{"issue":"3","key":"5_CR53","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s00415-004-0328-0","volume":"251","author":"G Linazasoro","year":"2004","unstructured":"Linazasoro G, Group SDAS (2004) Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson\u2019s disease. J Neurol 251(3):335\u2013339. https:\/\/doi.org\/10.1007\/s00415-004-0328-0","journal-title":"J Neurol"},{"issue":"15","key":"5_CR54","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/mds.23429","volume":"25","author":"CL Tomlinson","year":"2010","unstructured":"Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson\u2019s disease. Mov Disord 25(15):2649\u20132653. https:\/\/doi.org\/10.1002\/mds.23429","journal-title":"Mov Disord"},{"issue":"6","key":"5_CR55","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1212\/WNL.52.6.1227","volume":"52","author":"CG Goetz","year":"1999","unstructured":"Goetz CG, Blasucci L, Stebbins GT (1999) Switching dopamine agonists in advanced Parkinson\u2019s disease: is rapid titration preferable to slow? Neurology 52(6):1227\u20131229","journal-title":"Neurology"},{"issue":"9463","key":"5_CR56","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/S0140-6736(05)71083-7","volume":"365","author":"O Rascol","year":"2005","unstructured":"Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, Tolosa E, Group LS (2005) Rasagiline as an adjunct to levodopa in patients with Parkinson\u2019s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365(9463):947\u2013954. https:\/\/doi.org\/10.1016\/S0140-6736(05)71083-7","journal-title":"Lancet"},{"issue":"2","key":"5_CR57","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1001\/archneur.62.2.241","volume":"62","author":"Parkinson Study Group","year":"2005","unstructured":"Parkinson Study Group (2005) A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62(2):241\u2013248. https:\/\/doi.org\/10.1001\/archneur.62.2.241","journal-title":"Arch Neurol"},{"issue":"4","key":"5_CR58","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1001\/archneur.1994.00540160036006","volume":"51","author":"Parkinson Study Group","year":"1994","unstructured":"Parkinson Study Group (1994) A controlled trial of lazabemide (Ro 19-6327) in levodopa-treated Parkinson\u2019s disease. Parkinson Study Group. Arch Neurol 51(4):342\u2013347","journal-title":"Arch Neurol"},{"issue":"10","key":"5_CR59","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1002\/mds.26286","volume":"30","author":"M Murata","year":"2015","unstructured":"Murata M, Hasegawa K, Kanazawa I, Fukasaka J, Kochi K, Shimazu R (2015) Zonisamide improves wearing-off in Parkinson\u2019s disease: a randomized, double-blind study. Mov Disord 30(10):1343\u20131350. https:\/\/doi.org\/10.1002\/mds.26286","journal-title":"Mov Disord"},{"issue":"2","key":"5_CR60","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1001\/jamaneurol.2016.4467","volume":"74","author":"AH Schapira","year":"2017","unstructured":"Schapira AH, Fox SH, Hauser RA, Jankovic J, Jost WH, Kenney C, Kulisevsky J, Pahwa R, Poewe W, Anand R (2017) Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with parkinson disease and motor fluctuations: a randomized clinical trial. JAMA Neurol 74(2):216\u2013224. https:\/\/doi.org\/10.1001\/jamaneurol.2016.4467","journal-title":"JAMA Neurol"},{"issue":"2","key":"5_CR61","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/mds.25751","volume":"29","author":"R Borgohain","year":"2014","unstructured":"Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt M, Chirilineau D, Stocchi F, Lucini V, Giuliani R, Forrest E, Rice P, Anand R (2014) Randomized trial of safinamide add-on to levodopa in Parkinson\u2019s disease with motor fluctuations. Mov Disord 29(2):229\u2013237. https:\/\/doi.org\/10.1002\/mds.25751","journal-title":"Mov Disord"},{"issue":"5","key":"5_CR62","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1001\/archneur.65.5.577","volume":"65","author":"O Rascol","year":"2008","unstructured":"Rascol O, Poewe W, Lees A, Aristin M, Salin L, Juhel N, Waldhauser L, Schindler T (2008) Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study. Arch Neurol 65(5):577\u2013583. https:\/\/doi.org\/10.1001\/archneur.65.5.577","journal-title":"Arch Neurol"},{"key":"5_CR63","doi-asserted-by":"publisher","unstructured":"Deane KH, Spieker S, Clarke CE (2004) Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson\u2019s disease. Cochrane Database Syst Rev (4):CD004554. https:\/\/doi.org\/10.1002\/14651858.CD004554.pub2","DOI":"10.1002\/14651858.CD004554.pub2"},{"issue":"2","key":"5_CR64","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/S1474-4422(15)00336-1","volume":"15","author":"JJ Ferreira","year":"2016","unstructured":"Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P, investigators B-P (2016) Opicapone as an adjunct to levodopa in patients with Parkinson\u2019s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol 15(2):154\u2013165. https:\/\/doi.org\/10.1016\/S1474-4422(15)00336-1","journal-title":"Lancet Neurol"},{"key":"5_CR65","doi-asserted-by":"publisher","unstructured":"Torti M, Vacca L, Stocchi F (2018) Istradefylline for the treatment of Parkinson\u2019s disease: is it a promising strategy? Expert Opin Pharmacother:1\u20138. https:\/\/doi.org\/10.1080\/14656566.2018.1524876","DOI":"10.1080\/14656566.2018.1524876"},{"issue":"8","key":"5_CR66","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1002\/mds.25418","volume":"28","author":"Y Mizuno","year":"2013","unstructured":"Mizuno Y, Kondo T (2013) Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson\u2019s disease. Mov Disord 28(8):1138\u20131141. https:\/\/doi.org\/10.1002\/mds.25418","journal-title":"Mov Disord"},{"issue":"3","key":"5_CR67","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1212\/01.WNL.0000081227.84197.0B","volume":"61","author":"RA Hauser","year":"2003","unstructured":"Hauser RA, Hubble JP, Truong DD (2003) Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology 61(3):297\u2013303","journal-title":"Neurology"},{"issue":"2","key":"5_CR68","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.parkreldis.2011.09.023","volume":"18","author":"E Pourcher","year":"2012","unstructured":"Pourcher E, Fernandez HH, Stacy M, Mori A, Ballerini R, Chaikin P (2012) Istradefylline for Parkinson\u2019s disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study. Parkinsonism Relat Disord 18(2):178\u2013184. https:\/\/doi.org\/10.1016\/j.parkreldis.2011.09.023","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"5_CR69","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/s1474-4422(11)70012-6","volume":"10","author":"RA Hauser","year":"2011","unstructured":"Hauser RA, Cantillon M, Pourcher E, Micheli F, Mok V, Onofrj M, Huyck S, Wolski K (2011) Preladenant in patients with Parkinson\u2019s disease and motor fluctuations: a phase 2, double-blind, randomised trial. Lancet Neurol 10(3):221\u2013229. https:\/\/doi.org\/10.1016\/s1474-4422(11)70012-6","journal-title":"Lancet Neurol"},{"issue":"12","key":"5_CR70","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1001\/jamaneurol.2015.2268","volume":"72","author":"RA Hauser","year":"2015","unstructured":"Hauser RA, Stocchi F, Rascol O, Huyck SB, Capece R, Ho TW, Sklar P, Lines C, Michelson D, Hewitt D (2015) Preladenant as an adjunctive therapy with levodopa in Parkinson disease: two randomized clinical trials and lessons learned. JAMA Neurol 72(12):1491\u20131500. https:\/\/doi.org\/10.1001\/jamaneurol.2015.2268","journal-title":"JAMA Neurol"},{"issue":"8","key":"5_CR71","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/s1474-4422(14)70148-6","volume":"13","author":"RA Hauser","year":"2014","unstructured":"Hauser RA, Olanow CW, Kieburtz KD, Pourcher E, Docu-Axelerad A, Lew M, Kozyolkin O, Neale A, Resburg C, Meya U, Kenney C, Bandak S (2014) Tozadenant (SYN115) in patients with Parkinson\u2019s disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol 13(8):767\u2013776. https:\/\/doi.org\/10.1016\/s1474-4422(14)70148-6","journal-title":"Lancet Neurol"},{"issue":"1","key":"5_CR72","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1159\/000216839","volume":"62","author":"RA Hauser","year":"2009","unstructured":"Hauser RA, Bronzova J, Sampaio C, Lang AE, Rascol O, Theeuwes A, van de Witte SV, Group PS (2009) Safety and tolerability of pardoprunox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced Parkinson\u2019s disease. Eur Neurol 62(1):40\u201348. https:\/\/doi.org\/10.1159\/000216839","journal-title":"Eur Neurol"},{"issue":"4","key":"5_CR73","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.parkreldis.2011.12.006","volume":"18","author":"O Rascol","year":"2012","unstructured":"Rascol O, Bronzova J, Hauser RA, Lang AE, Sampaio C, Theeuwes A, van de Witte SV (2012) Pardoprunox as adjunct therapy to levodopa in patients with Parkinson\u2019s disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial. Parkinsonism Relat Disord 18(4):370\u2013376. https:\/\/doi.org\/10.1016\/j.parkreldis.2011.12.006","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"5_CR74","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/mds.23983","volume":"27","author":"A Lees","year":"2012","unstructured":"Lees A, Fahn S, Eggert KM, Jankovic J, Lang A, Micheli F, Mouradian MM, Oertel WH, Olanow CW, Poewe W, Rascol O, Tolosa E, Squillacote D, Kumar D (2012) Perampanel, an AMPA antagonist, found to have no benefit in reducing \u201coff\u201d time in Parkinson\u2019s disease. Mov Disord 27(2):284\u2013288. https:\/\/doi.org\/10.1002\/mds.23983","journal-title":"Mov Disord"},{"issue":"1","key":"5_CR75","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/WNF.0b013e318241520b","volume":"35","author":"O Rascol","year":"2012","unstructured":"Rascol O, Barone P, Behari M, Emre M, Giladi N, Olanow CW, Ruzicka E, Bibbiani F, Squillacote D, Patten A, Tolosa E (2012) Perampanel in Parkinson disease fluctuations: a double-blind randomized trial with placebo and entacapone. Clin Neuropharmacol 35(1):15\u201320. https:\/\/doi.org\/10.1097\/WNF.0b013e318241520b","journal-title":"Clin Neuropharmacol"},{"issue":"7","key":"5_CR76","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1002\/mds.22974","volume":"25","author":"K Eggert","year":"2010","unstructured":"Eggert K, Squillacote D, Barone P, Dodel R, Katzenschlager R, Emre M, Lees AJ, Rascol O, Poewe W, Tolosa E, Trenkwalder C, Onofrj M, Stocchi F, Nappi G, Kostic V, Potic J, Ruzicka E, Oertel W (2010) Safety and efficacy of perampanel in advanced Parkinson\u2019s disease: a randomized, placebo-controlled study. Mov Disord 25(7):896\u2013905. https:\/\/doi.org\/10.1002\/mds.22974","journal-title":"Mov Disord"},{"issue":"3","key":"5_CR77","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1002\/mds.22922","volume":"25","author":"O Rascol","year":"2010","unstructured":"Rascol O, Azulay JP, Blin O, Bonnet AM, Brefel-Courbon C, Cesaro P, Damier P, Debilly B, Durif F, Galitzky M, Grouin JM, Pennaforte S, Villafane G, Yaici S, Agid Y (2010) Orodispersible sublingual piribedil to abort OFF episodes: a single dose placebo-controlled, randomized, double-blind, cross-over study. Mov Disord 25(3):368\u2013376. https:\/\/doi.org\/10.1002\/mds.22922","journal-title":"Mov Disord"},{"issue":"9","key":"5_CR78","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1002\/mds.26611","volume":"31","author":"PA LeWitt","year":"2016","unstructured":"LeWitt PA, Hauser RA, Grosset DG, Stocchi F, Saint-Hilaire MH, Ellenbogen A, Leinonen M, Hampson NB, DeFeo-Fraulini T, Freed MI, Kieburtz KD (2016) A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson\u2019s disease. Mov Disord 31(9):1356\u20131365. https:\/\/doi.org\/10.1002\/mds.26611","journal-title":"Mov Disord"},{"issue":"6","key":"5_CR79","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/mds.870110607","volume":"11","author":"T van Laar","year":"1996","unstructured":"van Laar T, Neef C, Danhof M, Roon KI, Roos RA (1996) A new sublingual formulation of apomorphine in the treatment of patients with Parkinson\u2019s disease. Mov Disord 11(6):633\u2013638. https:\/\/doi.org\/10.1002\/mds.870110607","journal-title":"Mov Disord"},{"issue":"1","key":"5_CR80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00002826-199901000-00001","volume":"22","author":"W Ondo","year":"1999","unstructured":"Ondo W, Hunter C, Almaguer M, Gancher S, Jankovic J (1999) Efficacy and tolerability of a novel sublingual apomorphine preparation in patients with fluctuating Parkinson\u2019s disease. Clin Neuropharmacol 22(1):1\u20134","journal-title":"Clin Neuropharmacol"},{"issue":"4","key":"5_CR81","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/mds.870100405","volume":"10","author":"T van Laar","year":"1995","unstructured":"van Laar T, Jansen EN, Neef C, Danhof M, Roos RA (1995) Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson\u2019s disease: a study of five different suppositories. Mov Disord 10(4):433\u2013439. https:\/\/doi.org\/10.1002\/mds.870100405","journal-title":"Mov Disord"},{"issue":"9","key":"5_CR82","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1001\/archneur.58.9.1385","volume":"58","author":"RB Dewey Jr","year":"2001","unstructured":"Dewey RB Jr, Hutton JT, LeWitt PA, Factor SA (2001) A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 58(9):1385\u20131392","journal-title":"Arch Neurol"},{"issue":"11","key":"5_CR83","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.parkreldis.2014.08.010","volume":"20","author":"RA Hauser","year":"2014","unstructured":"Hauser RA, Isaacson S, Clinch T (2014) Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection. Parkinsonism Relat Disord 20(11):1171\u20131176. https:\/\/doi.org\/10.1016\/j.parkreldis.2014.08.010","journal-title":"Parkinsonism Relat Disord"},{"issue":"9","key":"5_CR84","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/mds.26697","volume":"31","author":"RA Hauser","year":"2016","unstructured":"Hauser RA, Olanow CW, Dzyngel B, Bilbault T, Shill H, Isaacson S, Dubow J, Agro A (2016) Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson\u2019s disease. Mov Disord 31(9):1366\u20131372. https:\/\/doi.org\/10.1002\/mds.26697","journal-title":"Mov Disord"},{"issue":"2","key":"5_CR85","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S1474-4422(18)30405-8","volume":"18","author":"PA LeWitt","year":"2019","unstructured":"LeWitt PA, Hauser RA, Pahwa R, Isaacson SH, Fernandez HH, Lew M, Saint-Hilaire M, Pourcher E, Lopez-Manzanares L, Waters C, Rudz\u00ednska M, Sedkov A, Batycky R, Oh C, Investigators S-PS (2019) Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol 18(2):145\u2013154. https:\/\/doi.org\/10.1016\/S1474-4422(18)30405-8","journal-title":"Lancet Neurol"},{"issue":"10","key":"5_CR86","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1002\/mds.23034","volume":"25","author":"E Wolf","year":"2010","unstructured":"Wolf E, Seppi K, Katzenschlager R, Hochschorner G, Ransmayr G, Schwingenschuh P, Ott E, Kloiber I, Haubenberger D, Auff E, Poewe W (2010) Long-term antidyskinetic efficacy of amantadine in Parkinson\u2019s disease. Mov Disord 25(10):1357\u20131363. https:\/\/doi.org\/10.1002\/mds.23034","journal-title":"Mov Disord"},{"issue":"7","key":"5_CR87","first-page":"588","volume":"109","author":"LR Zeldowicz","year":"1973","unstructured":"Zeldowicz LR, Hubermann J (1973) Long-term therapy of Parkinson\u2019s disease with amantadine, alone and combined with levodopa. Can Med Assoc J 109(7):588\u2013593","journal-title":"Can Med Assoc J"},{"issue":"8","key":"5_CR88","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1212\/WNL.25.8.695","volume":"25","author":"S Fahn","year":"1975","unstructured":"Fahn S, Isgreen WP (1975) Long-term evaluation of amantadine and levodopa combination in parkinsonism by double-blind corssover analyses. Neurology 25(8):695\u2013700","journal-title":"Neurology"},{"issue":"5","key":"5_CR89","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/1531-8257(200009)15:5<873::AID-MDS1017>3.0.CO;2-I","volume":"15","author":"E Luginger","year":"2000","unstructured":"Luginger E, Wenning GK, B\u00f6sch S, Poewe W (2000) Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson\u2019s disease. Mov Disord 15(5):873\u2013878","journal-title":"Mov Disord"},{"issue":"2","key":"5_CR90","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/00002826-200003000-00004","volume":"23","author":"BJ Snow","year":"2000","unstructured":"Snow BJ, Macdonald L, Mcauley D, Wallis W (2000) The effect of amantadine on levodopa-induced dyskinesias in Parkinson\u2019s disease: a double-blind, placebo-controlled study. Clin Neuropharmacol 23(2):82\u201385","journal-title":"Clin Neuropharmacol"},{"issue":"5","key":"5_CR91","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/1531-8257(200009)15:5<873::AID-MDS1017>3.0.CO;2-I","volume":"15","author":"E Luginger","year":"2000","unstructured":"Luginger E, Wenning GK, Bosch S, Poewe W (2000) Beneficial effects of amantadine on L-Dopa-induced dyskinesias in Parkinson\u2019s disease. Mov Disord 15(5):873\u2013878","journal-title":"Mov Disord"},{"issue":"5","key":"5_CR92","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1212\/WNL.50.5.1323","volume":"50","author":"L Verhagen Metman","year":"1998","unstructured":"Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN (1998) Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson\u2019s disease. Neurology 50(5):1323\u20131326","journal-title":"Neurology"},{"key":"5_CR93","doi-asserted-by":"publisher","unstructured":"Crosby NJ, Deane KH, Clarke CE (2003) Amantadine for dyskinesia in Parkinson\u2019s disease. Cochrane Database Syst Rev (2):CD003467. https:\/\/doi.org\/10.1002\/14651858.CD003467","DOI":"10.1002\/14651858.CD003467"},{"issue":"8","key":"5_CR94","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1001\/jamaneurol.2017.0943","volume":"74","author":"R Pahwa","year":"2017","unstructured":"Pahwa R, Tanner CM, Hauser RA, Isaacson SH, Nausieda PA, Truong DD, Agarwal P, Hull KL, Lyons KE, Johnson R, Stempien MJ (2017) ADS-5102 (Amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson disease (EASE LID study): a randomized clinical trial. JAMA Neurol 74(8):941\u2013949. https:\/\/doi.org\/10.1001\/jamaneurol.2017.0943","journal-title":"JAMA Neurol"},{"issue":"6","key":"5_CR95","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/mds.26159","volume":"30","author":"R Pahwa","year":"2015","unstructured":"Pahwa R, Tanner CM, Hauser RA, Sethi K, Isaacson S, Truong D, Struck L, Ruby AE, McClure NL, Went GT, Stempien MJ (2015) Amantadine extended release for levodopa-induced dyskinesia in Parkinson\u2019s disease (EASED study). Mov Disord 30(6):788\u2013795. https:\/\/doi.org\/10.1002\/mds.26159","journal-title":"Mov Disord"},{"issue":"12","key":"5_CR96","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/mds.27131","volume":"32","author":"W Oertel","year":"2017","unstructured":"Oertel W, Eggert K, Pahwa R, Tanner CM, Hauser RA, Trenkwalder C, Ehret R, Azulay JP, Isaacson S, Felt L, Stempien MJ (2017) Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson\u2019s disease (EASE LID 3). Mov Disord 32(12):1701\u20131709. https:\/\/doi.org\/10.1002\/mds.27131","journal-title":"Mov Disord"},{"issue":"3","key":"5_CR97","doi-asserted-by":"publisher","first-page":"511","DOI":"10.3233\/jpd-171134","volume":"7","author":"RA Hauser","year":"2017","unstructured":"Hauser RA, Pahwa R, Tanner CM, Oertel W, Isaacson SH, Johnson R, Felt L, Stempien MJ (2017) ADS-5102 (Amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson\u2019s disease (EASE LID 2 study): interim results of an open-label safety study. J Parkinsons Dis 7(3):511\u2013522. https:\/\/doi.org\/10.3233\/jpd-171134","journal-title":"J Parkinsons Dis"},{"key":"5_CR98","doi-asserted-by":"publisher","unstructured":"Hauser RA, Pahwa R, Wargin WA, Souza-Prien CJ, McClure N, Johnson R, Nguyen JT, Patni R, Went GT (2018) Pharmacokinetics of ADS-5102 (Amantadine) extended release capsules administered once daily at bedtime for the treatment of dyskinesia. Clin Pharmacokinet. https:\/\/doi.org\/10.1007\/s40262-018-0663-4","DOI":"10.1007\/s40262-018-0663-4"},{"issue":"4","key":"5_CR99","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s40263-018-0498-4","volume":"32","author":"LW Elmer","year":"2018","unstructured":"Elmer LW, Juncos JL, Singer C, Truong DD, Criswell SR, Parashos S, Felt L, Johnson R, Patni R (2018) Pooled analyses of phase III studies of ADS-5102 (Amantadine) extended-release capsules for dyskinesia in Parkinson\u2019s disease. CNS Drugs 32(4):387\u2013398. https:\/\/doi.org\/10.1007\/s40263-018-0498-4","journal-title":"CNS Drugs"},{"issue":"6","key":"5_CR100","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1002\/mds.26976","volume":"32","author":"SH Fox","year":"2017","unstructured":"Fox SH, Metman LV, Nutt JG, Brodsky M, Factor SA, Lang AE, Pope LE, Knowles N, Siffert J (2017) Trial of dextromethorphan\/quinidine to treat levodopa-induced dyskinesia in Parkinson\u2019s disease. Mov Disord 32(6):893\u2013903. https:\/\/doi.org\/10.1002\/mds.26976","journal-title":"Mov Disord"},{"issue":"1","key":"5_CR101","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1212\/WNL.51.1.203","volume":"51","author":"LV Metman","year":"1998","unstructured":"Metman LV, Del Dotto P, Natte R, van den Munckhof P, Chase TN (1998) Dextromethorphan improves levodopa-induced dyskinesias in Parkinson\u2019s disease. Neurology 51(1):203\u2013206","journal-title":"Neurology"},{"issue":"6","key":"5_CR102","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1097\/wnf.0000000000000241","volume":"40","author":"WJ Herring","year":"2017","unstructured":"Herring WJ, Assaid C, Budd K, Vargo R, Mazenko RS, Lines C, Ellenbogen A, Verhagen Metman L (2017) A phase Ib randomized controlled study to evaluate the effectiveness of a single-dose of the NR2B selective N-methyl-D-aspartate antagonist MK-0657 on levodopa-induced dyskinesias and motor symptoms in patients with parkinson disease. Clin Neuropharmacol 40(6):255\u2013260. https:\/\/doi.org\/10.1097\/wnf.0000000000000241","journal-title":"Clin Neuropharmacol"},{"issue":"5","key":"5_CR103","first-page":"273","volume":"22","author":"M Merello","year":"1999","unstructured":"Merello M, Nouzeilles MI, Cammarota A, Leiguarda R (1999) Effect of memantine (NMDA antagonist) on Parkinson\u2019s disease: a double-blind crossover randomized study. Clin Neuropharmacol 22(5):273\u2013276","journal-title":"Clin Neuropharmacol"},{"issue":"5","key":"5_CR104","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/ane.12468","volume":"133","author":"K Wictorin","year":"2016","unstructured":"Wictorin K, Widner H (2016) Memantine and reduced time with dyskinesia in Parkinson\u2019s disease. Acta Neurol Scand 133(5):355\u2013360. https:\/\/doi.org\/10.1111\/ane.12468","journal-title":"Acta Neurol Scand"},{"issue":"13","key":"5_CR105","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1002\/mds.25561","volume":"28","author":"F Stocchi","year":"2013","unstructured":"Stocchi F, Rascol O, Destee A, Hattori N, Hauser RA, Lang AE, Poewe W, Stacy M, Tolosa E, Gao H, Nagel J, Merschhemke M, Graf A, Kenney C, Trenkwalder C (2013) AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Mov Disord 28(13):1838\u20131846. https:\/\/doi.org\/10.1002\/mds.25561","journal-title":"Mov Disord"},{"issue":"9","key":"5_CR106","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1002\/mds.26659","volume":"31","author":"F Tison","year":"2016","unstructured":"Tison F, Keywood C, Wakefield M, Durif F, Corvol JC, Eggert K, Lew M, Isaacson S, Bezard E, Poli SM, Goetz CG, Trenkwalder C, Rascol O (2016) A phase 2A trial of the novel mGluR5-negative allosteric modulator dipraglurant for levodopa-induced dyskinesia in Parkinson\u2019s disease. Mov Disord 31(9):1373\u20131380. https:\/\/doi.org\/10.1002\/mds.26659","journal-title":"Mov Disord"},{"issue":"3","key":"5_CR107","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1212\/01.WNL.0000110317.52453.6C","volume":"62","author":"F Durif","year":"2004","unstructured":"Durif F, Debilly B, Galitzky M, Morand D, Viallet F, Borg M, Thobois S, Broussolle E, Rascol O (2004) Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology 62(3):381\u2013388","journal-title":"Neurology"},{"issue":"2","key":"5_CR108","first-page":"295","volume":"75","author":"R Katzenschlager","year":"2004","unstructured":"Katzenschlager R, Manson AJ, Evans A, Watt H, Lees AJ (2004) Low dose quetiapine for drug induced dyskinesias in Parkinson\u2019s disease: a double blind cross over study. J Neurol Neurosurg Psychiatry 75(2):295\u2013297","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"5_CR109","doi-asserted-by":"publisher","unstructured":"Kleiner-Fisman G, Herzog J, Fisman DN, Tamma F, Lyons KE, Pahwa R, Lang AE, Deuschl G (2006) Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord 21 Suppl 14:S290\u2013S304. https:\/\/doi.org\/10.1002\/mds.20962","DOI":"10.1002\/mds.20962"},{"issue":"9","key":"5_CR110","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa060281","volume":"355","author":"G Deuschl","year":"2006","unstructured":"Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Sch\u00e4fer H, B\u00f6tzel K, Daniels C, Deutschl\u00e4nder A, Dillmann U, Eisner W, Gruber D, Hamel W, Herzog J, Hilker R, Klebe S, Kloss M, Koy J, Krause M, Kupsch A, Lorenz D, Lorenzl S, Mehdorn HM, Moringlane JR, Oertel W, Pinsker MO, Reichmann H, Reuss A, Schneider GH, Schnitzler A, Steude U, Sturm V, Timmermann L, Tronnier V, Trottenberg T, Wojtecki L, Wolf E, Poewe W, Voges J, German Parkinson Study Group NuS (2006) A randomized trial of deep-brain stimulation for Parkinson\u2019s disease. N Engl J Med 355(9):896\u2013908. https:\/\/doi.org\/10.1056\/NEJMoa060281","journal-title":"N Engl J Med"},{"issue":"7","key":"5_CR111","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1205158","volume":"368","author":"WM Schuepbach","year":"2013","unstructured":"Schuepbach WM, Rau J, Knudsen K, Volkmann J, Krack P, Timmermann L, Halbig TD, Hesekamp H, Navarro SM, Meier N, Falk D, Mehdorn M, Paschen S, Maarouf M, Barbe MT, Fink GR, Kupsch A, Gruber D, Schneider GH, Seigneuret E, Kistner A, Chaynes P, Ory-Magne F, Brefel Courbon C, Vesper J, Schnitzler A, Wojtecki L, Houeto JL, Bataille B, Maltete D, Damier P, Raoul S, Sixel-Doering F, Hellwig D, Gharabaghi A, Kruger R, Pinsker MO, Amtage F, Regis JM, Witjas T, Thobois S, Mertens P, Kloss M, Hartmann A, Oertel WH, Post B, Speelman H, Agid Y, Schade-Brittinger C, Deuschl G (2013) Neurostimulation for Parkinson\u2019s disease with early motor complications. N Engl J Med 368(7):610\u2013622. https:\/\/doi.org\/10.1056\/NEJMoa1205158","journal-title":"N Engl J Med"},{"issue":"14","key":"5_CR112","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/mds.26024","volume":"29","author":"TA Mestre","year":"2014","unstructured":"Mestre TA, Espay AJ, Marras C, Eckman MH, Pollak P, Lang AE (2014) Subthalamic nucleus-deep brain stimulation for early motor complications in Parkinson\u2019s disease-the EARLYSTIM trial: early is not always better. Mov Disord 29(14):1751\u20131756. https:\/\/doi.org\/10.1002\/mds.26024","journal-title":"Mov Disord"},{"issue":"14","key":"5_CR113","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1002\/mds.26080","volume":"29","author":"WM Schupbach","year":"2014","unstructured":"Schupbach WM, Rau J, Houeto JL, Krack P, Schnitzler A, Schade-Brittinger C, Timmermann L, Deuschl G (2014) Myths and facts about the EARLYSTIM study. Mov Disord 29(14):1742\u20131750. https:\/\/doi.org\/10.1002\/mds.26080","journal-title":"Mov Disord"},{"issue":"1","key":"5_CR114","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/s1474-4422(12)70264-8","volume":"12","author":"VJ Odekerken","year":"2013","unstructured":"Odekerken VJ, van Laar T, Staal MJ, Mosch A, Hoffmann CF, Nijssen PC, Beute GN, van Vugt JP, Lenders MW, Contarino MF, Mink MS, Bour LJ, van den Munckhof P, Schmand BA, de Haan RJ, Schuurman PR, de Bie RM (2013) Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson\u2019s disease (NSTAPS study): a randomised controlled trial. Lancet Neurol 12(1):37\u201344. https:\/\/doi.org\/10.1016\/s1474-4422(12)70264-8","journal-title":"Lancet Neurol"},{"issue":"2","key":"5_CR115","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/mds.20276","volume":"20","author":"R Katzenschlager","year":"2005","unstructured":"Katzenschlager R, Hughes A, Evans A, Manson AJ, Hoffman M, Swinn L, Watt H, Bhatia K, Quinn N, Lees AJ (2005) Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson\u2019s disease: a prospective study using single-dose challenges. Mov Disord 20(2):151\u2013157. https:\/\/doi.org\/10.1002\/mds.20276","journal-title":"Mov Disord"},{"issue":"4","key":"5_CR116","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/mds.26067","volume":"30","author":"P Martinez-Martin","year":"2015","unstructured":"Martinez-Martin P, Reddy P, Katzenschlager R, Antonini A, Todorova A, Odin P, Henriksen T, Martin A, Calandrella D, Rizos A, Bryndum N, Glad A, Dafsari HS, Timmermann L, Ebersbach G, Kramberger MG, Samuel M, Wenzel K, Tomantschger V, Storch A, Reichmann H, Pirtosek Z, Trost M, Svenningsson P, Palhagen S, Volkmann J, Chaudhuri KR (2015) EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson\u2019s disease. Mov Disord 30(4):510\u2013516. https:\/\/doi.org\/10.1002\/mds.26067","journal-title":"Mov Disord"},{"issue":"7","key":"5_CR117","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1001\/archneur.61.7.1044","volume":"61","author":"RG Holloway","year":"2004","unstructured":"Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, McDermott M, Seibyl J, Weiner W, Musch B, Kamp C, Welsh M, Shinaman A, Pahwa R, Barclay L, Hubble J, LeWitt P, Miyasaki J, Suchowersky O, Stacy M, Russell DS, Ford B, Hammerstad J, Riley D, Standaert D, Wooten F, Factor S, Jankovic J, Atassi F, Kurlan R, Panisset M, Rajput A, Rodnitzky R, Shults C, Petsinger G, Waters C, Pfeiffer R, Biglan K, Borchert L, Montgomery A, Sutherland L, Weeks C, DeAngelis M, Sime E, Wood S, Pantella C, Harrigan M, Fussell B, Dillon S, Alexander-Brown B, Rainey P, Tennis M, Rost-Ruffner E, Brown D, Evans S, Berry D, Hall J, Shirley T, Dobson J, Fontaine D, Pfeiffer B, Brocht A, Bennett S, Daigneault S, Hodgeman K, O\u2019Connell C, Ross T, Richard K, Watts A, Group PS (2004) Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 61(7):1044\u20131053. https:\/\/doi.org\/10.1001\/archneur.61.7.1044","journal-title":"Arch Neurol"},{"issue":"11","key":"5_CR118","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2165\/00023210-200418110-00003","volume":"18","author":"F Bracco","year":"2004","unstructured":"Bracco F, Battaglia A, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL (2004) The long-acting dopamine receptor agonist cabergoline in early Parkinson\u2019s disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs 18(11):733\u2013746","journal-title":"CNS Drugs"},{"issue":"20","key":"5_CR119","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1056\/nejm200005183422004","volume":"342","author":"O Rascol","year":"2000","unstructured":"Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson\u2019s disease who were treated with ropinirole or levodopa. 056 study group. N Engl J Med 342(20):1484\u20131491. https:\/\/doi.org\/10.1056\/nejm200005183422004","journal-title":"N Engl J Med"},{"key":"5_CR120","doi-asserted-by":"publisher","unstructured":"Fox SH, Katzenschlager R, Lim SY, Ravina B, Seppi K, Coelho M, Poewe W, Rascol O, Goetz CG, Sampaio C (2011) The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson\u2019s disease. Mov Disord 26 Suppl 3:S2\u2013S41. https:\/\/doi.org\/10.1002\/mds.23829","DOI":"10.1002\/mds.23829"},{"issue":"3","key":"5_CR121","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.parkreldis.2014.10.032","volume":"21","author":"D Charles","year":"2015","unstructured":"Charles D, Konrad PE, Davis TL, Neimat JS, Hacker ML, Finder SG (2015) Deep brain stimulation in early stage Parkinson\u2019s disease. Parkinsonism Relat Disord 21(3):347\u2013348. https:\/\/doi.org\/10.1016\/j.parkreldis.2014.10.032","journal-title":"Parkinsonism Relat Disord"},{"issue":"10","key":"5_CR122","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.parkreldis.2015.08.008","volume":"21","author":"ML Hacker","year":"2015","unstructured":"Hacker ML, Tonascia J, Turchan M, Currie A, Heusinkveld L, Konrad PE, Davis TL, Neimat JS, Phibbs FT, Hedera P, Wang L, Shi Y, Shade DM, Sternberg AL, Drye LT, Charles D (2015) Deep brain stimulation may reduce the relative risk of clinically important worsening in early stage Parkinson\u2019s disease. Parkinsonism Relat Disord 21(10):1177\u20131183. https:\/\/doi.org\/10.1016\/j.parkreldis.2015.08.008","journal-title":"Parkinsonism Relat Disord"},{"key":"5_CR123","doi-asserted-by":"crossref","unstructured":"Goetz CG, Damier P, Hicking C, Laska E, Muller T, Olanow CW, Rascol O, Russ H (2007) Sarizotan as a treatment for dyskinesias in Parkinson\u2019s disease: a double-blind placebo-controlled trial. Mov Disord 22(2):179\u2013186. https:\/\/doi.org\/dx.doi.org\/10.1002\/mds.21226.","DOI":"10.1002\/mds.21226"},{"key":"5_CR124","doi-asserted-by":"crossref","unstructured":"Bara-Jimenez W, Bibbiani F, Morris MJ, Dimitrova T, Sherzai A, Mouradian MM, Chase TN (2005) Effects of serotonin 5-HT1A agonist in advanced Parkinson\u2019s disease. Mov Disord 20(8):932\u2013936. https:\/\/doi.org\/10.1002\/mds.20370.","DOI":"10.1002\/mds.20370"},{"key":"5_CR125","doi-asserted-by":"crossref","unstructured":"Lewitt PA, Hauser RA, Lu M, Nicholas AP, Weiner W, Coppard N, Leinonen M, Savola JM (2012) Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study). Neurology 79(2):163\u2013169. https:\/\/doi.org\/10.1212\/WNL.0b013e31825f0451.","DOI":"10.1212\/WNL.0b013e31825f0451"},{"key":"5_CR126","doi-asserted-by":"crossref","unstructured":"Manson AJ, Iakovidou E, Lees AJ (2000) Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson\u2019s disease. Mov Disord 15(2):336\u2013337.","DOI":"10.1002\/1531-8257(200003)15:2<336::AID-MDS1023>3.0.CO;2-R"},{"key":"5_CR127","doi-asserted-by":"crossref","unstructured":"Rascol O, Arnulf I, Peyro-Saint Paul H, Brefel-Courbon C, Vidailhet M, Thalamas C, Bonnet AM, Descombes S, Bejjani B, Fabre N, Montastruc JL, Agid Y (2001) Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson\u2019s disease. Mov Disord 16(4):708\u2013713.","DOI":"10.1002\/mds.1143"},{"key":"5_CR128","doi-asserted-by":"crossref","unstructured":"Svenningsson P, Rosenblad C, Af Edholm Arvidsson K, Wictorin K, Keywood C, Shankar B, Lowe DA, Bjorklund A, Widner H (2015) Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson\u2019s disease: a dose-finding study. Brain 138(Pt 4):963\u2013973. https:\/\/doi.org\/10.1093\/brain\/awu409","DOI":"10.1093\/brain\/awu409"},{"key":"5_CR129","doi-asserted-by":"crossref","unstructured":"Bonifati V, Fabrizio E, Cipriani R, Vanacore N, Meco G (1994) Buspirone in levodopa-induced dyskinesias. Clin Neuropharmacol 17(1):73\u201382.","DOI":"10.1097\/00002826-199402000-00008"},{"key":"5_CR130","unstructured":"Mestre TA, Shah B, Connolly B, de Aquino C, Al Dhakeel A, Walsh R, Prashanth LK, Ghate T, Lui J, Fox SH (2014) A pilot study evaluating the histamine H2 antagonist, famotidine, for levodopa-induced dyskinesia in Parkinson\u2019s disease. Mov Disord 29:S250\u2013S251."},{"key":"5_CR131","doi-asserted-by":"crossref","unstructured":"Carroll CB, Bain PG, Teare L, Liu X, Joint C, Wroath C, Parkin SG, Fox P, Wright D, Hobart J, Zajicek JP (2004) Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology 63(7):1245\u20131250. https:\/\/doi.org\/10.1212\/01.wnl.0000140288.48796.8e.","DOI":"10.1212\/01.WNL.0000140288.48796.8E"},{"key":"5_CR132","doi-asserted-by":"crossref","unstructured":"Sieradzan KA, Fox SH, Hill M, Dick JP, Crossman AR, Brotchie JM (2001) Cannabinoids reduce levodopa-induced dyskinesia in Parkinson\u2019s disease: a pilot study. Neurology 57(11):2108\u20132111.","DOI":"10.1212\/WNL.57.11.2108"},{"key":"5_CR133","doi-asserted-by":"crossref","unstructured":"Stathis P, Konitsiotis S, Tagaris G, Peterson D (2011) Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson\u2019s disease. Mov Disord 26(2):264\u2013270. https:\/\/doi.org\/10.1002\/mds.23355.","DOI":"10.1002\/mds.23355"},{"key":"5_CR134","doi-asserted-by":"crossref","unstructured":"Wolz M, Lohle M, Strecker K, Schwanebeck U, Schneider C, Reichmann H, Grahlert X, Schwarz J, Storch A (2010) Levetiracetam for levodopa-induced dyskinesia in Parkinson\u2019s disease: a randomized, double-blind, placebo-controlled trial. J Neural Trans 117(11):1279\u20131286. https:\/\/doi.org\/10.1007\/s00702-010-0472-x.","DOI":"10.1007\/s00702-010-0472-x"},{"key":"5_CR135","doi-asserted-by":"crossref","unstructured":"Kobylecki C, Burn DJ, Kass-Iliyya L, Kellett MW, Crossman AR, Silverdale MA (2014) Randomized clinical trial of topiramate for levodopa-induced dyskinesia in Parkinson\u2019s disease. Parkinsonism Relat Disord 20(4):452\u2013455. https:\/\/doi.org\/10.1016\/j.parkreldis.2014.01.016.","DOI":"10.1016\/j.parkreldis.2014.01.016"},{"key":"5_CR136","doi-asserted-by":"crossref","unstructured":"Price PA, Parkes JD, Marsden CD (1978) Sodium valproate in the treatment of levodopa-induced dyskinesia. JNNP 41(8):702\u2013706. https:\/\/doi.org\/10.1136\/jnnp.41.8.702.","DOI":"10.1136\/jnnp.41.8.702"},{"key":"5_CR137","doi-asserted-by":"crossref","unstructured":"Trenkwalder C, Berg D, Rascol O, Eggert K, Ceballos-Baumann A, Corvol JC, Storch A, Zhang L, Azulay JP, Broussolle E, Defebvre L, Geny C, Gostkowski M, Stocchi F, Tranchant C, Derkinderen P, Durif F, Espay AJ, Feigin A, Houeto JL, Schwarz J, Di Paolo T, Feuerbach D, Hockey HU, Jaeger J, Jakab A, Johns D, Linazasoro G, Maruff P, Rozenberg I, Sovago J, Weiss M, Gomez-Mancilla B (2016) A placebo-controlled trial of AQW051 in patients with moderate to severe levodopa-induced dyskinesia. Mov Disord 31(7):1049\u20131054. https:\/\/doi.org\/10.1002\/mds.26569.","DOI":"10.1002\/mds.26569"},{"key":"5_CR138","doi-asserted-by":"crossref","unstructured":"Lindeboom SF, Lakke JP (1978) Deanol and physostigmine in the treatment of L-dopa-induced dyskinesias. Acta Neurol Scand 58(2):134\u2013138.","DOI":"10.1111\/j.1600-0404.1978.tb02871.x"},{"key":"5_CR139","doi-asserted-by":"crossref","unstructured":"Rascol O, Fabre N, Blin O, Poulik J, Sabatini U, Senard JM, Ane M, Montastruc JL, Rascol A (1994) Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson\u2019s disease. Mov Disord 9(4):437\u2013440. https:\/\/doi.org\/10.1002\/mds.870090410.","DOI":"10.1002\/mds.870090410"},{"key":"5_CR140","doi-asserted-by":"crossref","unstructured":"Fox S, Silverdale M, Kellett M, Davies R, Steiger M, Fletcher N, Crossman A, Brotchie J (2004) Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson\u2019s disease. Mov Disord 19(5):554\u2013560. https:\/\/doi.org\/10.1002\/mds.10693.","DOI":"10.1002\/mds.10693"},{"key":"5_CR141","doi-asserted-by":"crossref","unstructured":"Rascol O, Ferreira J, Negre-Pages L, Perez-Lloret S, Lacomblez L, Galitzky M, Lemarie JC, Corvol JC, Brotchie JM, Bossi L (2012) A proof-of-concept, randomized, placebo-controlled, multiple cross-overs (n-of-1) study of naftazone in Parkinson\u2019s disease. Fund Clin Pharmacol 26(4):557\u2013564. https:\/\/doi.org\/10.1111\/j.1472-8206.2011.00951.x.","DOI":"10.1111\/j.1472-8206.2011.00951.x"},{"key":"5_CR142","doi-asserted-by":"crossref","unstructured":"Corvol JC, Durif F, Meissner WG, Azulay JP, Haddad R, Guimaraes-Costa R, Mariani LL, Cormier-Dequaire F, Thalamas C, Galitzky M, Boraud T, Debilly B, Eusebio A, Houot M, Dellapina E, Chaigneau V, Salis A, Lacomblez L, Benel L, Rascol O (2018) Naftazone in advanced Parkinson\u2019s disease: an acute L-DOPA challenge randomized controlled trial. Parkinsonism Relat Disord 60:51\u201356. https:\/\/doi.org\/10.1016\/j.parkreldis.2018.10.005.","DOI":"10.1016\/j.parkreldis.2018.10.005"},{"key":"5_CR143","doi-asserted-by":"crossref","unstructured":"Group PS (2001) Evaluation of dyskinesias in a pilot, randomized, placebo-controlled trial of remacemide in advanced Parkinson disease. Arc Neurol 58(10):1660\u20131668.","DOI":"10.1001\/archneur.58.10.1660"},{"key":"5_CR144","doi-asserted-by":"crossref","unstructured":"Arnulf I, Vidailhet M, Bonnet AM, Descombes S, Jaillon C, Agid Y, Brefel C, Rascol O, Xie J, Pollak P, Cattelin F (2001) Blockade of cholecystokinin-A receptors has no effect on dyskinesias in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 70(6):812\u2013813.","DOI":"10.1136\/jnnp.70.6.812"},{"key":"5_CR145","doi-asserted-by":"crossref","unstructured":"Reardon KA, Mendelsohn FA, Chai SY, Horne MK (2000) The angiotensin converting enzyme (ACE) inhibitor, perindopril, modifies the clinical features of Parkinson\u2019s disease. Aust N Z J Med 30(1):48\u201353.","DOI":"10.1111\/j.1445-5994.2000.tb01054.x"},{"key":"5_CR146","doi-asserted-by":"crossref","unstructured":"Blanchet PJ, Fang J, Hyland K, Arnold LA, Mouradian MM, Chase TN (1999) Short-term effects of high-dose 17beta-estradiol in postmenopausal PD patients: a crossover study. Neurology 53(1):91\u201395.","DOI":"10.1212\/WNL.53.1.91"}],"container-title":["Neuromethods","Clinical Trials In Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-0912-5_5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T02:03:08Z","timestamp":1662170588000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-0912-5_5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,18]]},"ISBN":["9781071609118","9781071609125"],"references-count":146,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-0912-5_5","relation":{},"ISSN":["0893-2336","1940-6045"],"issn-type":[{"type":"print","value":"0893-2336"},{"type":"electronic","value":"1940-6045"}],"subject":[],"published":{"date-parts":[[2020,8,18]]},"assertion":[{"value":"18 August 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}